What is Kallyope?
Kallyope is a pioneering biotechnology company dedicated to the discovery and development of novel therapeutics targeting the gut-brain axis. Leveraging a sophisticated, cross-disciplinary approach, the company integrates cutting-edge technologies in sequencing, bioinformatics, neural imaging, cellular and molecular biology, and human genetics. This comprehensive strategy aims to unlock a deeper understanding of gut-brain biology, paving the way for transformative treatments designed to enhance human health. The company's strategic location at the Alexandria Center® for Life Science in New York City places it within a vibrant hub of scientific innovation and collaboration.
How much funding has Kallyope raised?
Kallyope has raised a total of $486.1M across 5 funding rounds:
Private Equity
$28.1M
Series A
$44M
Series B
$66M
Series C
$112M
Series D
$236M
Private Equity (2015): $28.1M, investors not publicly disclosed
Series A (2015): $44M led by Lux Capital, The Column Group, Alexandria Venture, Polaris Partners, and Illumina Inc
Series B (2018): $66M supported by EUCLIDEAN CAPITAL, The Column Group, Polaris Partners, Two Sigma Ventures, Illumina Ventures, Lux Capital, and Alexandria Venture Investments
Series C (2020): $112M featuring Lux Capital, Alexandria Venture Investments, Casdin Capital , LLC, Greenspring Associates Inc, The Column Group, Polaris Partners, Bill Gates, Two Sigma Ventures, Illumina Ventures, and Euclidean Capital
Series D (2022): $236M backed by Mubadala and The Column Group
Key Investors in Kallyope
Lux Capital
Lux Capital is a New York-based venture capital firm that invests in early-stage and growth-stage companies at the intersection of science and technology, backing founders in frontier areas such as AI, robotics, space, defense, biotechnology, and advanced materials.
Alexandria Venture Investments
Alexandria Real Estate Equities, Inc., a real estate investment trust (REIT), engages in the ownership, operation, management, development, acquisition, and redevelopment of properties for the life sciences industry, offering properties for lease primarily to universities and independent not-for-profit institutions, as well as pharmaceutical, biotechnology, and medical device companies.
The Column Group
The Column Group (TCG) is a venture ecosystem focused on advancing scientific innovation in the life sciences sector, supporting the formation and growth of companies and employing an edge-to-edge investment model that nurtures early-stage technology platforms and later-stage programs.
What's next for Kallyope?
The significant capital infusion, particularly the recent major strategic investment, positions Kallyope for accelerated growth and expansion of its research and development initiatives. This backing is expected to fuel the advancement of its therapeutic candidates through critical clinical stages and further solidify its position in the biotechnology landscape. The company's focus on the complex gut-brain axis suggests a long-term vision for addressing unmet medical needs, with future developments likely centered on translating its scientific discoveries into tangible patient benefits. Continued investment and strategic partnerships will be key to Kallyope's trajectory in bringing innovative treatments to market.
See full Kallyope company page
